Tandem Diabetes Care, Guardion Health, GT Biopharma among healthcare movers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2024
0mins
- Gainers: Biodexa Pharmaceuticals ADR (BDRX) up by 63%, Xylo Technologies ADR (XYLO) up by 25%, GT Biopharma (GTBP) up by 18%, Guardion Health Sciences (GHSI) up by 11%, Tandem Diabetes Care (TNDM) up by 9%.
- Losers: American Oncology Network (AONC) down by 20%, MyMD Pharmaceuticals (MYMD) down by 13%, SAB Biotherapeutics (SABS) down by 12%, Lucy Scientific Discovery (LSDI) down by 10%, Exscientia ADR (EXAI) down by 7%.
- S&P 500 Health Care Sector: Increased by 0.54% to 1707.08. Health Care Equipment & Services increased by 0.11% to 1958.99. Pharmaceuticals, Biotechnology & Life Science, contributing 58% to the index, increased by 0.84% to 1409.64.
- Health Care Select Sector SPDR: Articles discuss healthcare being ripe for buying despite patent cliff, a pivotal week of earnings for healthcare stocks, and how fundamentals don't support overweighting health care.
- Short Interest in S&P 500 Healthcare Sector: Short interest dipped in April, with biotechnology companies being the most shorted. Health care is considered crowded but trades at a discount compared to historical trends according to Bank of America.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNDM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNDM
Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 26.33 USD with a low forecast of 14.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
8 Buy
10 Hold
0 Sell
Moderate Buy
Current: 19.760
Low
14.00
Averages
26.33
High
55.00
Current: 19.760
Low
14.00
Averages
26.33
High
55.00
About TNDM
Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rosen Law Firm Investigates TNDM Securities Claims
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing materially misleading business information, indicating significant legal risks for the company.
- Stock Price Plunge: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting market concerns over the company's transparency.
- Class Action Preparation: The firm is preparing a class action lawsuit, allowing investors to seek compensation without any out-of-pocket fees, which may attract more affected investors and increase the likelihood of successful claims.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling such cases.
Continue Reading
Rosen Law Firm Investigates Securities Claims for Tandem Diabetes Care
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) for possibly issuing misleading business information, indicating significant deficiencies in the company's transparency.
- Stock Price Impact: On August 7, 2025, Tandem Diabetes' stock plummeted by 19.9% following a press release regarding a voluntary medical device correction for the t:slim X2 insulin pumps, reflecting serious market concerns over the company's governance and product safety.
- Class Action Preparation: The firm is preparing a class action for affected investors, allowing them to seek compensation without upfront costs, highlighting the legal risks the company faces and potential impacts on its future financial performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and success in handling similar cases, which may provide robust legal support for investors.
Continue Reading